fda authorizes another test that detects neutralizing antibodies from recent or prior sars-cov-2 infection
fda authorizes another test that detects neutralizing antibodies from recent or prior sars-cov-2 infection
the ability to detect neutralizing antibodies can help us gain additional insight into what the existence of antibodies may mean for patients as we continue the fight against covid-19, said tim stenzel, m.d., ph.d., director of the office of in vitro diagnostics and radiological health in the fdas center for devices and radiological health.", "the fda issued an emergency use authorization (eua) for the cpass sars-cov-2 neutralization antibody detection kit, which specifically detects this type of antibody.", 


































"there are still many unknowns about what the presence of sars-cov-2 antibodies may tell us about potential immunity, but todays authorization gives us another tool to evaluate those antibodies as we continue to research and study this virus.")